CompletedPHASE2, PHASE3NCT01522235
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy
Studying OBSOLETE: Other ganglionopathy related to autoimmune diseases
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beth Israel Deaconess Medical Center
- Principal Investigator
- Roy Freeman, MDBeth Israel Deaconess Medical Center
- Intervention
- Double blinded IVIg(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2012 – 2015
Study locations (6)
- Nih Ninds, Bethesda, Maryland, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- NYU Medical Center, New York, New York, United States
- Vanderbilt University, Nashville, Tennessee, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
Collaborators
Mayo Clinic · Vanderbilt University · NYU Langone Health · University of Texas Southwestern Medical Center · National Institute of Neurological Disorders and Stroke (NINDS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01522235 on ClinicalTrials.gov